Active surveillance in patients with a complete clinical response after neoadjuvant chemoradiotherapy for esophageal- and gastroesophageal junction cancer

Tamara J. Huizer*, Sjoerd M. Lagarde, Joost J. M. E. Nuyttens, Lindsey Oudijk, Manon C. W. Spaander, Roelf Valkema, Bianca Mostert, Bas P. L. Wijnhoven, SANO study group

*Corresponding author for this work

Research output: Contribution to journalReview articleAcademicpeer-review

7 Downloads (Pure)

Abstract

Neoadjuvant chemoradiotherapy in patients with esophageal- and gastroesophageal junction cancer induces tumor regression. In approximately one fourth of patients, this leads to a pathological complete response in the resection specimen. Hence, active surveillance may be an alternative strategy in patients without residual disease after neoadjuvant chemoradiotherapy. Previous studies have shown that the combination of esophagogastroduodenoscopy with bite-on-bite biopsies, endoscopic ultrasound with fine needle aspiration of suspected lymph nodes, and a PET-CT-scan can be considered adequate for the detection of residual disease. So far, it has been unclear whether active surveillance with surgery as needed is a safe treatment option and leads to non-inferior overall survival compared to standard esophagectomy after neoadjuvant chemoradiotherapy. This review will discuss the current status of active surveillance for esophageal and junctional cancer.
Original languageEnglish
Number of pages9
JournalInnovative Surgical Sciences
DOIs
Publication statusE-pub ahead of print - 7 Nov 2024

Bibliographical note

Publisher Copyright:
© 2024 the author(s),

Fingerprint

Dive into the research topics of 'Active surveillance in patients with a complete clinical response after neoadjuvant chemoradiotherapy for esophageal- and gastroesophageal junction cancer'. Together they form a unique fingerprint.

Cite this